FAQ

ISIS 5132

Known as: ISIS 5132/CGP69846A, ISIS-5132, ISIS5132 
A synthetic, 20-base antisense oligodeoxynucleotide that hybridizes to c-raf kinase messenger RNA. ISIS 5132 has been shown to specifically suppress… (More)
National Institutes of Health

Topic mentions per year

Topic mentions per year

1996-2014
024619962014

Related topics

Related topics

5 relations

Broader (4)

Antineoplastic AgentsAntisense OligonucleotidesEnzyme InhibitorsThionucleotides

Narrower (1)

CGP 69846A

Related mentions per year

Related mentions per year

1947-2018
19401960198020002020
ISIS 5132
Antineoplastic Agents
Enzyme Inhibitors
Antisense Oligonucleotides
CGP 69846A
Thionucleotides

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2009
2009
Phase I study of the c-raf-1 antisense oligonucleotide ISIS 5132 in combination with carboplatin and paclitaxel in patients with previously untreated, advanced non-small cell lung cancer.
BACKGROUND A phase I trial was performed to evaluate the administration of carboplatin/paclitaxel in combination with ISIS-5132… (More)
Is this relevant?
2006
2006
Plasma protein binding of an antisense oligonucleotide targeting human ICAM-1 (ISIS 2302).
In vitro ultrafiltration was used to determine the plasma protein-binding characteristics of phosphorothioate oligonucleotides… (More)
Is this relevant?
2003
2003
Phase II study of CGP 69846A (ISIS 5132) in recurrent epithelial ovarian cancer: an NCIC clinical trials group study (NCIC IND.116).
OBJECTIVE ISIS 5132 is a 20-base phosphorothioate DNA oligonucleotide against human c-raf kinase, a downstream effector of ras… (More)
Is this relevant?
2002
2002
A randomized phase II and pharmacokinetic study of the antisense oligonucleotides ISIS 3521 and ISIS 5132 in patients with hormone-refractory prostate cancer.
PURPOSE Protein kinase C (PKC)-alpha and Raf-1 are important elements of proliferative signal transduction pathways in both… (More)
  • table 1
  • table 2
  • table 3
  • table 4
  • table 5
Is this relevant?
2002
2002
Phase II randomized study of ISIS 3521 and ISIS 5132 in patients with locally advanced or metastatic colorectal cancer: a National Cancer Institute of Canada clinical trials group study.
BACKGROUND Because treatment of metastatic colon cancer is noncurative, new treatments are needed. This trial evaluated the… (More)
  • table 1
  • table 2
  • table 3
Is this relevant?
2001
2001
Phase I Trial of ISIS 5132, an antisense oligonucleotide inhibitor of c-raf-1, administered by 24-hour weekly infusion to patients with advanced cancer.
Raf-1 is a serine/threonine kinase that functions as a critical effector of Ras-mediated signal transduction via the mitogen… (More)
  • table 1
  • table 2
  • table 3
  • figure 1
  • table 4
Is this relevant?
2001
2001
Phase II trial with ISIS 5132 in patients with small-cell (SCLC) and non-small cell (NSCLC) lung cancer. A European Organization for Research and Treatment of Cancer (EORTC) Early Clinical Studies…
Two multicentre phase II trials were designed to determine if tumour responses can be achieved in progressive small-cell lung… (More)
Is this relevant?
2000
2000
A phase I trial of c-Raf kinase antisense oligonucleotide ISIS 5132 administered as a continuous intravenous infusion in patients with advanced cancer.
Raf proteins play a central role in the mitogen-activated protein kinase signaling pathway and hence are involved in oncogenic… (More)
  • table 1
  • table 2
  • table 3
  • table 4
  • figure 1
Is this relevant?
1999
1999
Phase I clinical/pharmacokinetic and pharmacodynamic trial of the c-raf-1 antisense oligonucleotide ISIS 5132 (CGP 69846A).
PURPOSE Raf-1 is a protein kinase that plays a broad role in oncogenic signaling and acts as a downstream effector of Ras in the… (More)
Is this relevant?
1999
1999
c-raf-1 depletion and tumor responses in patients treated with the c-raf-1 antisense oligodeoxynucleotide ISIS 5132 (CGP 69846A).
Abnormally regulated signaling through proliferative signal transduction pathways characterizes many of the common solid tumors… (More)
  • figure 1
  • table 1
  • figure 2
Is this relevant?